Arrowhead Pharmaceuticals, Inc.

Equities

ARWR

US04280A1007

Market Closed - Nasdaq Other stock markets 20:00:00 11/03/2026 GMT			5-day change	1st Jan Change
58.10 ^USD	-1.86%		-10.75%	-12.49%

02-22	Certain Warrants of Arrowhead Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 22-FEB-2026.	CI
02-22	Certain Options of Arrowhead Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 22-FEB-2026.	CI

Transcript : Arrowhead Pharmaceuticals, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 11

Published on 05/14/2025 at 12:30 pm BST - Modified on 05/14/2025 at 07:20 pm BST

S&P Capital IQ

Presenter Speech
Jason Gerberry (Analysts)

We're going to get going here with our next company presenter at the BofA Annual Healthcare Conference. Pleased to be introducing Arrowhead Pharmaceuticals

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Arrowhead Pharmaceuticals, Inc.

02-22	Certain Warrants of Arrowhead Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 22-FEB-2026.	CI
02-22	Certain Options of Arrowhead Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 22-FEB-2026.	CI
02-22	Certain Common Stock of Arrowhead Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 22-FEB-2026.	CI
02-09	Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to S&P 400 - Biotechnology	CI
02-09	Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to S&P 400 Health Care	CI
02-09	Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to S&P 400	CI
02-09	Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) dropped from S&P 600 Health Care	CI
02-09	Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) dropped from S&P 600	CI
02-06	Arrowhead Pharmaceuticals, Inc., Q1 2026 Earnings Call, Feb 05, 2026
02-05	Earnings Flash (ARWR) Arrowhead Pharmaceuticals, Inc. Reports Q1 Revenue $264.0M, vs. FactSet Est of $213.9M	MT
02-05	Earnings Flash (ARWR) Arrowhead Pharmaceuticals, Inc. Reports Q1 Revenue $264.0M, vs. FactSet Est of $213.9M	MT
02-05	Arrowhead Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2025	CI
02-04	Ciena Set to Join S&P500	MT
01-27	Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA - the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia	CI
01-27	Arrowhead Pharmaceuticals Doses First Subject in Clinical Trial of Treatment for Mixed Hyperlipidemia	MT